133 related articles for article (PubMed ID: 9279289)
21. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.
Grassegger A; Fritsch P; Reider N
Dermatol Surg; 2001 Jan; 27(1):47-52. PubMed ID: 11231243
[TBL] [Abstract][Full Text] [Related]
22. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
[TBL] [Abstract][Full Text] [Related]
23. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
24. The anticoagulant effect of heparan sulfate and dermatan sulfate.
Teien AN; Abildgaard U; Höök M
Thromb Res; 1976 Jun; 8(6):859-67. PubMed ID: 134464
[No Abstract] [Full Text] [Related]
25. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
Hoppensteadt D; Walenga JM; Fareed J
Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
[TBL] [Abstract][Full Text] [Related]
26. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
Davenport A
Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
[TBL] [Abstract][Full Text] [Related]
27. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
Gill J; Kovacs MJ
Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
[TBL] [Abstract][Full Text] [Related]
28. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.
Elalamy I; Lecrubier C; Potevin F; Abdelouahed M; Bara L; Marie JP; Samama M
Thromb Haemost; 1995 Nov; 74(5):1384-5. PubMed ID: 8607131
[No Abstract] [Full Text] [Related]
29. Hirudin in heparin-induced thrombocytopenia.
Lubenow N; Greinacher A
Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
[TBL] [Abstract][Full Text] [Related]
30. Delayed-type skin reaction to the heparin-alternative danaparoid.
Szolar-Platzer C; Aberer W; Kränke B
J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
[TBL] [Abstract][Full Text] [Related]
31. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis.
He S; Blombäck M; Bark N; Johnsson H; Wallén NH
Thromb Haemost; 2010 May; 103(5):1076-84. PubMed ID: 20216982
[TBL] [Abstract][Full Text] [Related]
32. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
Lindhoff-Last E; Bauersachs R
Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
[TBL] [Abstract][Full Text] [Related]
33. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults.
Ignjatovic V; Summerhayes R; Yip YY; Monagle P
Thromb Res; 2008; 122(5):709-14. PubMed ID: 18384841
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the activity of a heparan sulphate of defined molecular weight range (7500-15,000 Da) with heparin and dermatan sulphate.
Gervasi GB; Catalani R; Bartoli C; Carpita G; Farina C; Gelso E
Pharmacol Res; 1995 Jun; 31(6):331-6. PubMed ID: 8685069
[TBL] [Abstract][Full Text] [Related]
35. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation.
Hollenstein UM; Pernerstorfer T; Homoncik M; Hansen JB; Finzen H; Handler S; Jilma B
J Infect Dis; 2002 Nov; 186(9):1270-6. PubMed ID: 12402196
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of APC resistance in patients on standard or low molecular weight heparin.
Gilmore G; Thom J; Baker RI
Thromb Haemost; 1996 Feb; 75(2):372-3. PubMed ID: 8815593
[No Abstract] [Full Text] [Related]
37. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
[TBL] [Abstract][Full Text] [Related]
38. Additional anticoagulant strategies for managing heparin-induced thrombocytopenia.
Nawarskas JJ; Spinler SA
Am J Health Syst Pharm; 1996 Apr; 53(8):945. PubMed ID: 8728386
[No Abstract] [Full Text] [Related]
39. The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats.
Fujishima Y; Yokota K; Sukamoto T
Thromb Res; 1998 Sep; 91(5):221-7. PubMed ID: 9755834
[TBL] [Abstract][Full Text] [Related]
40. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
